Activity of ofloxacin against Mycobacterium leprae in the mouse. 1988

J H Grosset, and C C Guelpa-Lauras, and E G Perani, and C Beoletto
Département de Bactériologie-Virologie, Faculté de Médecine Pitié-Salpêtrière, Paris, France.

Mice inoculated with 4800 Mycobacterium leprae in the left hind foot pad were treated from day 62 to day 150 after infection with 50 mg or 150 mg of ofloxacin per kg body weight, 150 mg pefloxacin per kg, or 50 mg prothionamide per kg. These drugs were administered by esophageal cannula 5 days weekly with dapsone (0.01 g per 100 g diet). Multiplication of M. leprae in the treated and in untreated control mice was assessed by monthly harvests. The treatment of mice with the smaller dosage ofloxacin, with pefloxacin, prothionamide, or dapsone uniformly resulted in a delay of multiplication of 4 months, compared to the multiplication of M. leprae in the untreated controls. The delay of multiplication (4 months) being 1 month longer than the duration of drug administration (3 months), all of the treatments may be considered as bacteriopausal or moderately bactericidal. In contast with these results, treatment of mice with 150 mg ofloxacin per kg resulted in no growth of the organisms whatever as late as 18 months after inoculation, strongly suggesting that, in that dosage, ofloxacin had killed all of the M. leprae. Such a profound killing activity has been observed only with rifampin. Although the pharmacokinetic characteristics of ofloxacin are different in man from those in the mouse, the daily dosage of 150 mg ofloxacin per kg body weight in the mouse is equivalent to 400 mg per day in man which is the usual therapeutic dosage; thus, the results obtained in the mouse may be extrapolated to man. Therefore, ofloxacin appears a very promising drug for the chemotherapy of leprosy.

UI MeSH Term Description Entries
D007918 Leprosy A chronic granulomatous infection caused by MYCOBACTERIUM LEPRAE. The granulomatous lesions are manifested in the skin, the mucous membranes, and the peripheral nerves. Two polar or principal types are lepromatous and tuberculoid. Hansen's Disease,Hansen Disease
D009166 Mycobacterium leprae A species of gram-positive, aerobic bacteria that causes LEPROSY in man. Its organisms are generally arranged in clumps, rounded masses, or in groups of bacilli side by side.
D009643 Norfloxacin A synthetic fluoroquinolone (FLUOROQUINOLONES) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA GYRASE. AM-0715,AM-715,MK-0366,MK-366,MK0366,MK366,Noroxin,AM 0715,AM 715,AM0715,MK 0366,MK 366
D010078 Oxazines Six-membered heterocycles containing an oxygen and a nitrogen.
D011515 Prothionamide Antitubercular agent similar in action and side effects to ETHIONAMIDE. It is used mostly in combination with other agents. Ektebin,Peteha,Protionamide
D003622 Dapsone A sulfone active against a wide range of bacteria but mainly employed for its actions against MYCOBACTERIUM LEPRAE. Its mechanism of action is probably similar to that of the SULFONAMIDES which involves inhibition of folic acid synthesis in susceptible organisms. It is also used with PYRIMETHAMINE in the treatment of malaria. (From Martindale, The Extra Pharmacopoeia, 30th ed, p157-8) Diaminodiphenylsulfone,Sulfonyldianiline,4,4'-Diaminophenyl Sulfone,Avlosulfone,DADPS,Dapsoderm-X,Dapson-Fatol,Diaphenylsulfone,Disulone,Sulfona,4,4' Diaminophenyl Sulfone,Sulfone, 4,4'-Diaminophenyl
D005260 Female Females
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial
D015242 Ofloxacin A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION. DL-8280,DR-3355,Hoe-280,ORF-28489,Ofloxacin Hydrochloride,Ofloxacine,Ru-43280,Tarivid,DL 8280,DL8280,DR 3355,DR3355,Hoe 280,Hoe280,ORF 28489,ORF28489,Ru 43280,Ru43280

Related Publications

J H Grosset, and C C Guelpa-Lauras, and E G Perani, and C Beoletto
April 1987, Antimicrobial agents and chemotherapy,
J H Grosset, and C C Guelpa-Lauras, and E G Perani, and C Beoletto
March 1993, Arzneimittel-Forschung,
J H Grosset, and C C Guelpa-Lauras, and E G Perani, and C Beoletto
March 1993, International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association,
J H Grosset, and C C Guelpa-Lauras, and E G Perani, and C Beoletto
September 1980, Annales de la Societe belge de medecine tropicale,
J H Grosset, and C C Guelpa-Lauras, and E G Perani, and C Beoletto
September 1992, International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association,
J H Grosset, and C C Guelpa-Lauras, and E G Perani, and C Beoletto
September 1991, Leprosy review,
J H Grosset, and C C Guelpa-Lauras, and E G Perani, and C Beoletto
April 2020, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy,
J H Grosset, and C C Guelpa-Lauras, and E G Perani, and C Beoletto
November 1990, Kekkaku : [Tuberculosis],
J H Grosset, and C C Guelpa-Lauras, and E G Perani, and C Beoletto
January 1997, Journal of the Formosan Medical Association = Taiwan yi zhi,
J H Grosset, and C C Guelpa-Lauras, and E G Perani, and C Beoletto
May 1975, The American review of respiratory disease,
Copied contents to your clipboard!